Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


August 29, 2015 3:45 PM ET

Pharmaceuticals

Company Overview of Lupin Pharmaceuticals, Inc.

Company Overview

Lupin Pharmaceuticals, Inc. engages in the development and manufacture of branded and generic pharmaceutical products. It offers generic pharmaceutical products for a range of therapeutic areas; and generic Gatifloxacin Ophthalmic Solution for the treatment of bacterial conjunctivitis. The company also engages in identifying, developing, and marketing prescription drugs for children through distributors in the United States; and manufactures oral and injectable cephalosporin APIs. In addition, it offers oral contraceptives for the prevention of pregnancy in women. Lupin Pharmaceuticals, Inc. was founded in 2003 and is based in Baltimore, Maryland. The company has plants in Mandideep, Auranga...

111 South Calvert Street

Harborplace Tower

21st Floor

Baltimore, MD 21202

United States

Founded in 2003

Phone:

410-576-2000

Fax:

410-576-2221

Key Executives for Lupin Pharmaceuticals, Inc.

Chief Executive Officer and Managing Director
Age: 47
Compensation as of Fiscal Year 2015.

Lupin Pharmaceuticals, Inc. Key Developments

Horizon Pharma plc Files Patent Infringement Lawsuits Against Actavis Laboratories UT, Inc., Actavis, Inc., Allergan plc, Amneal Pharmaceuticals, LLC, IGI Laboratories, Inc., Lupin Ltd., Lupin Pharmaceuticals, Inc., Taro Pharmaceuticals USA, Inc. and Taro Pharmaceutical Industries, Ltd

Horizon Pharma plc announced it has filed patent infringement lawsuits in the United States District Court for the District of New Jersey against Actavis Laboratories UT, Inc., Actavis, Inc., and Allergan plc (collectively Actavis), Amneal Pharmaceuticals, LLC (Amneal), IGI Laboratories, Inc. (IGI), Lupin Ltd. and Lupin Pharmaceuticals, Inc. (Lupin), and Taro Pharmaceuticals USA, Inc. and Taro Pharmaceutical Industries Ltd. (collectively Taro) related to Abbreviated New Drug Applications filed with the U.S. Food and Drug Administration to market a generic version of PENNSAID(r) (diclofenac sodium topical solution) 2% w/w (PENNSAID 2%). The lawsuits claim infringement of Horizon's newly issued U.S. Patent No. 9,066,913 titled 'Diclofenac Topical Formulation', which covers PENNSAID 2%.

Lilly and Acrux File Patent Infringement Lawsuit Against Lupin Pharma

Acrux announced that Eli Lilly and Co., Eli Lilly Export S.A., and Acrux DDS Pty Ltd. have filed a lawsuit against Lupin Pharmaceuticals Inc. for infringement of issued US patents that cover Axiron. The patents are owned by Acrux DDS Pty Ltd, a wholly-owned subsidiary of Acrux Limited, and are exclusively licensed to Lilly. The lawsuit was filed in the United States District Court for the Southern District of Indiana in response to a notice letter sent by Lupin regarding its filing with the FDA of an Abbreviated New Drug Application (ANDA) for a Testosterone Metered Dose Transdermal Solution. The letter stated that the ANDA contains Paragraph IV certifications with respect to US Patents 8,419,307, 8,435,944, 8,784,878, 8,807,861 and 8,993,520, which are expected to expire between 2026 and 2030. These patents include claims relating to the application of testosterone formulations to the underarm and to the applicator used to apply Axiron.

Lupin Pharmaceuticals Inc. Launches Amlodipine and Valsartan Tablets in US

Lupin Pharmaceuticals Inc. has launched its Amlodipine and Valsartan Tablets, 5 mg/160 mg, 10 mg/160 mg, 5 mg/320 mg and 10 mg/320 mg, which are the AB rated generic equivalent of Novartis Pharmaceuticals Corporation's Exforge tablets 5 mg/160 mg, 10 mg/160 mg, 5 mg/320 mg and 10 mg/320mg strengths. Lupin had received final approval from the United States Food and Drug Administration (FDA) for the product. Lupin's Amlodipine and Valsartan Tablets is the combination tablet of Amlodipine, a dihydropyridine calcium channel blocker (DHP CCB) and Valsartan, an angiotensin II receptor blocker (ARB). Lupin's Amlodipine and Valsartan tablets are indicated for the treatment of hypertension and to lower blood pressure: In patients not adequately controlled on monotherapy; As initial therapy in patients likely to need multiple drugs to achieve their blood pressure goals. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. Exforge Tablets had U.S sales of USD 414.9 million.

Similar Private Companies By Industry

Company Name Region
Viral Oncotherapies, Inc United States
Aurora Pharmaceutical, LLC United States
Endo Pharmaceuticals Colorado LLC United States
ApopLogic Pharmaceuticals LLC United States
Documedics United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Lupin Pharmaceuticals, Inc., please visit www.lupinpharmaceuticals.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.